Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1101
Shown on this page
12
Current sort
Recently updated
Campus scope
UCLA Health, Los Angeles, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCLA Health, Los Angeles, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 877–888 of 1,101 matching trials with a site at UCLA Health, Los Angeles, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 3 Interventional

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

NCT06165341
Status at this site: Recruiting
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran Injection, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Not applicable Interventional

Intercostal Cryoanalgesia in Double Lung Transplant Recipients

NCT07281118
Status at this site: Recruiting
View directory record Official record
Conditions
Post-operative Pain Management
Interventions
Atricure CryoSPHERE MAX Probe
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating AI-Generated Plain Language Summaries on Patient Comprehension of Ophthalmology Notes Among English-Speaking Patients

NCT06859216
Status at this site: Recruiting
View directory record Official record
Conditions
Ophthalmic Disease, Artifical Intelligence, Large Language Model
Interventions
AI-Generated Plain Language Summaries
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

NCT04416984
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Interventions
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Genetic · Biological · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Not applicable Interventional

Postpartum Continuous Glucose Monitoring for Type 2 Diabetes Mellitus Risk Evaluation in Patients With Gestational Diabetes Mellitus: POSTPOD Trial

NCT07449039
Status at this site: Recruiting
View directory record Official record
Conditions
Gestational Diabetes Mellitus in Pregnancy
Interventions
Continuous Glucose Monistor
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100
Site status not listed — check the official record
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Selpercatinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Stockton, California • Torrance, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Active, not recruiting Phase 3 Interventional Results available

Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT05316701
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Orca-T, Standard-of-Care
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Phase 4 Interventional

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304
Status at this site: Recruiting
View directory record Official record
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Active, not recruiting Not applicable Interventional

Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array

NCT06598059
Site status not listed — check the official record
View directory record Official record
Conditions
Hearing Loss
Interventions
Cochlear implant, Dexamethasone
Device · Drug
Lead sponsor
Cochlear
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Englewood, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Phase 2 Interventional

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

NCT06410209
Status at this site: Recruiting
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Discussion, Goal Setting, Interview, Media Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Reward, Text Message-Based Navigation Intervention
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
15 Years to 20 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Not applicable Interventional

Impact of Prebiotics in Ulcerative Colitis

NCT06495658
Status at this site: Recruiting
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Prebiotic
Dietary Supplement
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 9, 2026, 6:10 PM EST
Recruiting Phase 3 Interventional

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

NCT06112314
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Brenetafusp, Nivolumab, Nivolumab + Relatlimab
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 9, 2026, 6:10 PM EST

About this UCLA Health institution page

What this page lists
ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.